AGE/RAGE Axis in the development of abdominal aortic aneurysm

Annals of Surgery

Volumn 252, Issue 1, 2010, Pages 203-205

  Fujita, Tetsuji ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; GELATINASE B;

ABDOMINAL AORTA ANEURYSM; AORTA INTIMA; AORTA MEDIA; DIABETES MELLITUS; ENZYME ACTIVITY; LETTER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; THICKNESS;

ANIMALS; AORTIC ANEURYSM, ABDOMINAL; DIABETES MELLITUS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; RATS; RECEPTORS, IMMUNOLOGIC;

EID: 77954070998     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181e495e6     Document Type: Letter

References (17)

1. Zhang F, Kent KC, Yamanouchi D, et al. Anti-receptor for advanced glycation end products therapies as novel treatment for abdominal aortic aneurysm. Ann Surg. 2009;250:416-423.
2. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest. 2000;105:1605-1612.
3. Vazzana N, Santilli F, Curccurullo C, et al. Soluble form of RAGE in internal medicine. Intern Emerg Med. 2009;4:389-401. doi 10.1007/s11739-009- 0300-301
4. Diehm N, Dick F, Schaffner T, et al. Novel insight into the pathobiology of abdominal aortic aneurysm and potential future treatment concepts. Prog Cardiovasc Dis. 2007;50:209-217.
5. Nazratun N, Mahmood AA, Kuppusamy UR, et al. Diabetes mellitus exacerbates advanced glycation end product accumulation in the veins of end-stage renal failure patients. Vasc Med. 2006;11:245-250.
6. Basta G, Sironi AM, Lazzerini G, et al. Circulating soluble receptor for advanced glyca-tion end products is inversely associated with glycemic control S100A12 protein. J Clin Endo-crinol Metab. 2006;91:4628-4634.
7. Portik-Dobos V, Anstadt MP, Hutchinson J, et al. Evidence for a matrix metalloproteinase induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes. Diabetes. 2002;51:3063-3068.
8. Semba RD, Najjar SS, Sun K, et al. Serum car-boxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity. Am J Hypertens. 2009;22:74-79.
9. Walcher D, Marx N. Advanced glycation end products and C-peptide-modulators in diabetic vasculopathy and atherogenesis. Semin Immuno-pathol. 2009;31:103-111.
10. Astrand H, Ryden-Ahlgren A, Sundkrist G, et al. Reduced aortic wall stress in diabetes mellitus. Eur J Vasc Endovasc Surg. 2007;33:592-598.
11. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312:117-121.
12. Nishijo N, Sugiyama F, Kimoto K, et al. Salt-sensitive aortic aneurysm and rupture in hypertensive transgenic mice that overproduce an-giotensin II. Lab Invest. 1998;78:1059-1066.
13. Baxter BT, Terrin MC, Dalman RJ. Medical management of small abdominal aortic aneurysms. Circulation. 2008;119:1883-1889.
14. Weintraub NL. Understanding abdominal aortic aneurysm. N Engl J Med. 2009;361:1114-1116.
15. Powell JT. Final 12-year follow-up of surgery versus surveillance in the UK Small Aneurysm Trial. Br J Surg. 2007;94:21-26.
16. Fujita T. Effect of statins on proteolytic activity in the wall of abdominal aortic aneurysms (Letter). Br J Surg. 2008;95:667.
17. Lederle FA, Johnson GR, Wilson SE, et al; An-eurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Prevalence and associations of abdominal aortic an-eurysm detected through screening. Ann Int Med. 1997;126:441-449.